达克替尼联合西妥昔单抗治疗晚期非小细胞肺癌的临床疗效及生存情况分析

doi:10.3969/j.issn.1671-7171.2024.03.028

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1193 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical efficacy and survival of dacomitinib combined with cetuximab in the treatment of advanced non-small cell lung cancer(NSCLC). 【Methods】A total of 204 patients with advanced NSCLC were randomly divided into the control group and the observation group, with 102 cases in each group. The control group was given cetuximab treatment, and the observation group was given dacomitinib orally in addition to cetuximab. In both groups, medication continued until disease progression or toxic intolerance. The anti-tumor efficacy, tumor marker changes, lung function and adverse drug reactions of the two groups were compared after 3 courses of continuous treatment, and the 1-year survival was also analyzed between the two groups. 【Results】In the observation group, 3 patients dropped off due to incomplete treatment, and 5 cases dropped off in the control group. Finally, 99 cases in the observation group and 97 cases in the control group were included, respectively. The clinical control rate of the observation group was higher than that of the control group(P< 0.05). The levels of tumor-specific growth factor(TSGF), cell proliferation antigen(PCNA), carcinoembryonic antigen(CEA) after treatment were lower than those before treatment. And the levels of TSGF, PCNA and CEA in the observation group after treatment were lower than those in the control group(P<0.05). The forced vital capacity(FVC) and forced expiratory volume in the first second(FEV₁) /FVC in the two groups after treatment were higher than those before treatment(P<0.05), while those in the observation group were higher after treatment(P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05). By the end of follow-up, 2 cases in the control group and 1 case in the observation group were lost to follow-up. From the 1-year survival survey, 62 of 98 patients survived in the observation group and 47 of 95 patients survived in the control group. The 1-year overall survival curve of the observation group was better than that of the control group(P<0.05). 【Conclusion】Dacomitinib combined with Cetuximab in the treatment of advanced NSCLC can enhance anti-tumor efficacy, reduce tumor marker levels, and improve short-term survival.

Key words： Carcinoma, Non-Small-Cell Lung/DT Antibodies, Monoclonal/TU Treatment Outcome Survival Rate

Received: 10 October 2023

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.03.028 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I3/420

[1] ALZOFON N, JIMENO A. Capmatinib for non-small cell lung cancer[J].Drugs Today(Barc),2021, 57(1):17-25.
[2] DOHOPOLSKI M, IYENGAR P. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy[J].Ann Palliat Med,2021, 10(5):5944-5953.
[3] SACCO A G, CHEN R, WORDEN F P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial[J].Lancet Oncol,2021, 22(6):883-892.
[4] NILSSON F O L, GAL P, HOUISSE I, et al. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer(EGFRm NSCLC) in Sweden[J].J Med Econ,2021, 24(1):447-457.
[5] 中华医学会, 中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志, 2018, 40(12):935-964.
[6] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009, 45(2):228-247.
[7] 高东宸. 药物不良反应监察指南[M]. 北京:中国医药科技出版社,1996:48-51.
[8] 段昕波, 曹晓慈, 杜东杰. 达克替尼通过抑制EGFR表达促白介素-6诱导非小细胞癌细胞株A549凋亡的效果[J].毒理学杂志, 2020, 34(1):51-56.
[9] PATY J, SANDIN R, REISMAN A, et al. The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the phase Ⅲ trial ARCHER 1050[J].Future Oncol,2021, 17(7):783-794.
[10] PISCITELLI J, CHEN J, LABADIE R R, et al. The effect of hepatic impairment on the pharmacokinetics of Dacomitinib[J].Clin Drug Investig,2022, 42(3):221-235.
[11] MOK T S, CHENG Y, ZHOU X, et al. Updated overall survival in a randomized study comparing Dacomitinib with Gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations[J].Drugs,2021, 81(2):257-266.
[12] NAKAGAWA K, MATSUMURA K, SCORY T, et al. Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population[J].Future Oncol,2021, 17(1):103-115.